RecruitingOvarian CancerLung AdenocarcinomaEndometrial Cancer
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
Eligible age
18–130 yrs
Accepts
All genders
Locations
10 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This research is designed to determine if experimental treatment with Antibody-drug conjugate, AZD5335, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced tumors
Sponsor: AstraZeneca
Where it's recruiting
California
Duarte · Irvine · La Jolla
Colorado
Aurora
Kentucky
Louisville
Massachusetts
Boston
Michigan
Detroit
Ohio
Columbus
Oregon
Portland
Rhode Island
Providence
Texas
Houston
Virginia
Fairfax
Source: ClinicalTrials.gov · NCT05797168 · last updated 2026-10-05